You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development and evaluation of an internet based adaptation of the New Beginnings Program for divorced parents
SBC: Family Transitions- Programs that Work, LLC Topic: NICHDPROJECT ABSTRACT The proposed research builds on a successful Phase I SBIR grant to develop and test a web based version of a parenting after divorce group interventionthe New Beginnings Programwhich has been shown in two randomized trials to reduce youthsproblem behaviors and enhance their developmental competencies in theyear period after their parents participatedThe proposed web based format w ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
High-throughput nanoMEA-based Proarrhythmia Assay
SBC: CURI BIO, INC. Topic: NHLBIPROJECT SUMMARY Failure of new drugs at late stages of development is an extremely costly event commonly associated with the detection of unexpected arrhythmogenic properties in novel drugs Undetected arrhythmia inducing effects are also a common reason for drug withdrawal from the market As a result the FDA now mandates that all new drugs be tested for potential arrhythmogenic properties which ha ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Complex 3-Dimensional in vitro Human Skin Tissue Models for Scleroderma
SBC: CELDARA MEDICAL, LLC Topic: NIAMSPROJECT SUMMARY Sclerodermasystemic sclerosisSScis an autoimmune disease of unknown etiology that is characterized by vascular dysfunctionfibrosisand inflammationOne in three patients dies withinyears of diagnosisgiving SSc the highest case fatality rate of any systemic autoimmune diseaseA lack of biologically relevant SSc disease models has created a critical unmet need for more efficient preclin ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Interstitial Intensity Modulated Photodynamic Therapy Phase II
SBC: SIMPHOTEK, INC. Topic: 102Photodynamic therapy (PDT) is a cancer treatment that utilizes visible or near-infrared light to activate a light- sensitive drug (photosensitizer, PS) that, in turn, creates reactive singlet oxygen species from ground triplet state oxygen that is present in the tumor. The resulting reactive products induce tissue death. Ideally the reactive species will be produced within only the target volume, ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Dual View Endoscopy for Colonoscopy
SBC: OMNISCIENT IMAGING INC Topic: 102AbstractAn estimatedmillion colonoscopies are performed annually in the US at a cost of about $Bhowever current colonoscopes with forward vision fail to detectof precancerous polypsOverof the missed polyps are located on or behind numerous folds in the colon where they are hidden from the sight of a forward view colonoscopeIn this research proposalwe propose to complete our development of an imagi ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing
SBC: TWINSTRAND BIOSCIENCES INC Topic: 102Nearly a quarter of a million new cases of ovarian cancer are identified every year worldwide and the majority of these woman will die from their disease. When detected early, surgical cure rates exceed 90%, but currently most cases are detected at an advanced stage when the cancer has already disseminated. As such, our most pressing problem in ovarian cancer is a lack of tools to identify early s ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Optimization and Validation of an indicator cell assay for blood-based diagnosis of lung cancer
SBC: PRECYTE INC Topic: 102Project Summary. The Indicator Cell Assay Platform (iCAP) is an inexpensive blood-based assay that can be used for early detection of disease, disease stage stratification, prognosis and response to therapy for a variety of diseases. The iCAP uses cultured, standardized cells as biosensors, capitalizing on the ability of cells to respond to disease signals present in serum with exquisite sensitivi ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Targeting leukocyte metabolism to treat human autoimmune disease
SBC: Immunext, Inc. Topic: RImmuNext has defined an anti-MCT1 monoclonal antibody (mAb) that will be developed for the treatment of human autoimmune disease. The membrane monocarboxylate nutrient transporter SLC16A1 (MCT1) is a multi-pass transmembrane protein responsible for the facilitated transport of critical metabolites, including products of glycolysis: lactate, pyruvate and ketones. Our strong preliminary data support ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Improved cleaning technology for reducing risk of transmitting infection in endoscopy.
SBC: ADVANCED BIODEVICES LLC Topic: R7. Project Summary/Abstract: Outbreaks of infection caused by contaminated endoscopes are a serious public health problem that has even resulted in patient deaths. Currently, because of the narrowness of the channels and complexity of the endoscope, there simply is no reliable way of achieving this. The existing cleaning protocols also are highly dependent on operator technique. Accordingly, this ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
SBC: Syntrix Biosystems, Inc. Topic: 102The chemokine receptors CXCR1 and CXCR2 (CXCR1/2) are validated as having essential roles in the growth, survival, motility, invasion and angiogenesis of human melanoma, which secretes abundant amounts of the corresponding chemokine ligands, including CXCL8. Additionally, abnormal cancer-induced immunosuppressive myeloid-derived suppressor cells (MDSCs) in the circulation and tumor correlate with ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health